We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
Read MoreHide Full Article
Abbott (ABT - Free Report) is on a healthy growth trajectory of late. The stock has gained 4.8% over the last three months, ahead of the S&P 500’s 2.5% gain and the broader industry’s 1.5% decline.
The stock has a market cap of $89.9 billion. The company’s current-year growth rate is also favorable at 13.1% compared with the 4.5% increase of the broader industry. With solid prospects, this Zacks Rank #2 (Buy) stock emerges an attractive pick.
The Illinois-based medical device major’s estimate revision trend for the current year has also been positive. In the past couple of months, seven analysts moved north with just one movement in the opposite direction. The estimates were marginally revised upward from $2.48 per share to $2.49 over the same time frame.
The company also has a trailing four-quarter average positive earnings surprise of 4.6%.
Let’s find out whether the recent positive trend is a sustainable one.
The market is upbeat about Abbott gaining national reimbursement for FreeStyleLibre glucose monitoring system from National Health Service (NHS) Business Services Authority in the United Kingdom. This has been a major breakthrough in diabetics business.The reimbursement grant will make FreeStyleLibre system widely available to around 3.5 million people in the United Kingdom.
Also, other developments including Abbott’srecent FDA approval of Full MagLev HeartMate 3 Left Ventricular Assist Device (LVAD) are encouraging.
In addition, the company announced receipt of a national reimbursement for its FreeStyle Libre glucose monitoring system in Japan. This breakthrough has widened the medical device major’s customer base in diabetes management.
The company also recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust. Abbott expects this alliance to solidify footprint in the rapidly-growing diagnostics market.
Abbott’s second-quarter performance has been promising with sales and adjusted earnings from continuing operations increasing year over year. With several strategic progresses made, we expect this growth stream to continue in days ahead.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.5% over the last six months.
Chemed has a long-term expected earnings growth rate of 10%. The stock has gained 3.3% over the last six months.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has gained 3.5% over the last six months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
Image: Bigstock
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
Abbott (ABT - Free Report) is on a healthy growth trajectory of late. The stock has gained 4.8% over the last three months, ahead of the S&P 500’s 2.5% gain and the broader industry’s 1.5% decline.
The stock has a market cap of $89.9 billion. The company’s current-year growth rate is also favorable at 13.1% compared with the 4.5% increase of the broader industry. With solid prospects, this Zacks Rank #2 (Buy) stock emerges an attractive pick.
The Illinois-based medical device major’s estimate revision trend for the current year has also been positive. In the past couple of months, seven analysts moved north with just one movement in the opposite direction. The estimates were marginally revised upward from $2.48 per share to $2.49 over the same time frame.
The company also has a trailing four-quarter average positive earnings surprise of 4.6%.
Let’s find out whether the recent positive trend is a sustainable one.
The market is upbeat about Abbott gaining national reimbursement for FreeStyleLibre glucose monitoring system from National Health Service (NHS) Business Services Authority in the United Kingdom. This has been a major breakthrough in diabetics business.The reimbursement grant will make FreeStyleLibre system widely available to around 3.5 million people in the United Kingdom.
Also, other developments including Abbott’srecent FDA approval of Full MagLev HeartMate 3 Left Ventricular Assist Device (LVAD) are encouraging.
In addition, the company announced receipt of a national reimbursement for its FreeStyle Libre glucose monitoring system in Japan. This breakthrough has widened the medical device major’s customer base in diabetes management.
The company also recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust. Abbott expects this alliance to solidify footprint in the rapidly-growing diagnostics market.
Abbott’s second-quarter performance has been promising with sales and adjusted earnings from continuing operations increasing year over year. With several strategic progresses made, we expect this growth stream to continue in days ahead.
Other Key Picks
Other top-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , Chemed Corporation (CHE - Free Report) and Amedisys, Inc. (AMED - Free Report) . While Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), Chemed and Amedisys carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.5% over the last six months.
Chemed has a long-term expected earnings growth rate of 10%. The stock has gained 3.3% over the last six months.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has gained 3.5% over the last six months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>